| Literature DB >> 29186165 |
Sébastien Lamy1,2,3, Denis Ducros4, Chloé Diméglio1,3,5, Hélène Colineaux1,3,5, Romain Fantin3, Eloïse Berger3, Pascale Grosclaude3,6,7, Cyrille Delpierre3, Béatrice Bouhanick1,3,8.
Abstract
This research investigates the influence of place of residence and diabetic patient's socioeconomic position on their use of health services in a universal health care system. This retrospective cross-sectional population-based study is based on the joint use of the Health Insurance information systems, an ecological indicator of social deprivation and an indicator of potential spatial accessibility of healthcare provision in the Midi-Pyrénées region. Using French healthcare insurance population-based data on reimbursement of out-of-hospital care during the year 2012, we study the use of health services among patients aged 50 and over (n = 90,136).We built logistic regression models linking health services use to socioeconomic position by geographic area, adjusted for age, gender, healthcare provision, information regarding patients precariousness, and long-term condition, used as proxy for the state of health. After adjustment for healthcare provision, the lower population density in the geographical area of concern, the lower the access to specialised care, independent of the patients' SEP. General practitioner attendance was higher among the patients with the lowest SEP without being clearly influenced by their living place. We found no clear influence of either patients' SEP or their living place on their access to biological follow-up. This study is an attempt to account for the geographical context and to go further in studying the social determinants of health among diabetes patients.Entities:
Mesh:
Year: 2017 PMID: 29186165 PMCID: PMC5706715 DOI: 10.1371/journal.pone.0188295
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The level of urbanisation of the IRIS of the Midi-Pyrénées region.
Fig 2Being treated for diabetes (i.e. intake of at least three anti-diabetic drugs during the year) by SEP and living place among individuals aged 50 or over in the Midi-Pyrénées region (n = 957,911).
Results from a logistic model adjusted for SEP by geographical area, age, sex, exemption from co-payment due to long-term condition.
The characteristics of the 90,136 patients aged 50 or over and treated for diabetes in the Midi-Pyrénées region.
| Toulouse metropolis | others large urban areas | Midi-Pyrénées region except the large urban areas | |||||
|---|---|---|---|---|---|---|---|
| (n = 16,412) | (n = 39,048) | (n = 34,676) | |||||
| n | % | n | % | n | % | ||
| 70 | ±10.6 | 71 | ±10.5 | 72 | ±10.3 | ||
| 1,872 | 11.4 | 4,847 | 12.4 | 840 | 2.4 | ||
| 1,425 | 8.7 | 4,662 | 11.9 | 1,746 | 5.0 | ||
| 1,026 | 6.3 | 4,088 | 10.5 | 2,455 | 7.1 | ||
| 1,240 | 7.6 | 4,282 | 11.0 | 3,687 | 10.6 | ||
| 1,247 | 7.6 | 4,450 | 11.4 | 4,224 | 12.2 | ||
| 1,233 | 7.5 | 4,523 | 11.6 | 5,557 | 16.0 | ||
| 1,449 | 8.8 | 3,313 | 8.5 | 5,785 | 16.7 | ||
| 2,102 | 12.8 | 3,633 | 9.3 | 4,653 | 13.4 | ||
| 1,749 | 10.7 | 2,261 | 5.8 | 4,232 | 12.2 | ||
| 3,069 | 18.7 | 2,989 | 7.7 | 1,497 | 4.3 | ||
| 8,734 | 53.2 | 21,178 | 54.2 | 18,712 | 54.0 | ||
| 7,678 | 46.8 | 17,870 | 45.8 | 15,964 | 46.0 | ||
| 15,278 | 93.1 | 37923 | 97.1 | 33,876 | 97.7 | ||
| 1,134 | 6.9 | 1,125 | 2.9 | 800 | 2.3 | ||
| 2,865 | 17.5 | 6,101 | 15.6 | 5,048 | 14.6 | ||
| 13,547 | 82.5 | 32,947 | 84.4 | 29,628 | 85.4 | ||
| 104 | 45 | 75 | 43 | 79 | 51 | ||
| 12 | 3 | 6 | 3 | 3 | 3 | ||
| 2 | 2 | 5 | 7 | 10 | 14 | ||
1 Toulouse metropolis encompasses 37 municipalities. It corresponds to the most significant large urban areas of the region.
2 med (IQR) stands for median with interquartile range (IQR = q3 –q1)
Fig 3Access to medical follow-up by SEP and living place among patients aged 50 or over treated for diabetes.
(n = 90,136). Results from a logistic model adjusted for SEP by geographical area, age, sex, exemption from co-payment due to long-term condition, universal complementary healthcare insurance, and potentially localised accessibility to the GP (for therapeutic follow-up) / ophthalmologist (for prevention of complications).
Fig 4Access to biological monitoring (microalbuminura and glycated haemoglobin) by SEP and living place among patients aged 50 or over treated for diabetes.
(n = 90,136). Results from a logistic model adjusted for SEP by geographical area, age, sex, exemption from co-payment due to long-term condition, universal complementary healthcare insurance, and distance from the nearest medical laboratory.